SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.
Chronic kidney disease patients who experience pruritus after dialysis can now get relief from the first FDA-approved treatment for the condition. Cara Therapeutics received the FDA’s green light for its injectable drug, Korsuva.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
In addition to monetary damages and the guilty pleas, the government is seeking to transform the maker of OxyContin into a public benefit company that would fund efforts to curb opioid abuse and give away drugs to prevent overdose deaths.
The company filed for Chapter 11 Monday, but the move was criticized by some, particularly attorneys general in Massachusetts and Connecticut, amid reports that the Sackler family wired about $1 billion to overseas accounts.
Citing unnamed sources, news outlets reported that Purdue would be dissolved to create a new company that would sell OxyContin and use proceeds to pay plaintiffs in more than 2,000 lawsuits filed by governments nationwide.
Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in about 2,000 lawsuits regarding the drug.
Loxo's shares were up 65 percent on the news. The company won FDA accelerated approval on Nov. 26 for its tissue-agnostic cancer drug, Vitrakvi.
That the drug will only be given to patients shown through testing to harbor a genetic anomaly that increases the odds of a response makes its approval an important milestone in the evolution of value-based care.
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
Interim data from the Phase I data show 77 percent overall response rate, including 74 percent confirmed responses.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
Pitney Bowes on Thursday introduced Single Customer View. It's not an explicitly healthcare-focused product, but it underpins a big push into this industry.
The TED talks have built a brand around influential thought leaders known for their keen ability to deliver compelling insights on complex subjects on a minimalist stage. Although TEDMED has changed ownership a few times since 1998, it’s established itself as a must-see conference with exciting perspectives in healthcare and medical technology accompanied by innovative […]